News

Virginia Catalyst Announces Grant Round 15 Awarded Projects

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These four collaborative projects, involving Virginia research universities and industry partners, were awarded through Virginia Catalyst Grant Round 15 to address major unmet healthcare needs and drive job creation and capital formation in Virginia.

Through this 15th round of funding, Virginia Catalyst has awarded 61 grants totaling $29.7 million, resulting in over $47 million in matching funds and an additional $821 million in follow-on funding to date.

Grant Round 15 awarded projects:

Project: Transforming Asthma Treatment with a New Generation A2B Adenosine Receptor Antagonist

  • Company: Adovate, LLC  (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project: Optimization of a Wearable Enteral Feeding System for Commercialization

  • Company: Luminoah, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $463,000

Project: Pre-clinical Evaluation of an Implant Device for the Regeneration of Severe Osteochondral Defects, Utilizing a Proven Novel Material and 3D Printing

  • Company: Nanochon, Inc. (Washington, DC)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $445,000

Project: Blocking the S1P Pathway for Chronic Kidney Disease Therapeutics

  • Company: S1P Therapeutics, Inc. (Blacksburg, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $500,000

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …